Multi-Antigenic Peptide(s) Vaccine and Immunogen for Conferring Streptococcus pneumoniae Immunity

Disease caused by Streptococcus pneumoniae (pneumococcus) is an important cause of morbidity and mortality in the United States and developing countries. Pneumococcal disease is prevalent among the very young, the elderly and immunocompromised individuals. This invention is an improved, immunogenic peptide construct consisting of a combination of antigenic epitopes of the PsaA (37-kDa) protein from S. pneumoniae. In addition, the peptides of the invention have the capability of serving as specific immunogens in a subject, effectively eliciting the production of antibodies and conferring protective immunity against S. pneumoniae infection following immunognen administration.

Potential Commercial Applications: Competitive Advantages:
  • Development or improvement of S. pneumoniae vaccines
  • Public health vaccination programs
  • Clinical serodiagnostic development
  • May provide better immune protection than current, single-epitope based vaccines
  • Broader spectrum of S. pneumoniae serotypes addressed
  • Immunization with these peptides was shown to reduce carriage in murine studies

George Carlone (CDC)
Edwin Ades (CDC)
Jacquelyn Sampson (CDC)
Scott Johnson (CDC)
Danny Jue (CDC)

Intellectual Property:
US Application No. 09/613,092
PCT Application No. PCT/US2001/021626
US Application No. 11/145,814
US Application No. 12/360,382
Various international patent applications pending or issued

Licensing Contact:
Tara Kirby , Ph.D.
NIH Office of Technology Transfer
Phone: 301-435-4426

OTT Reference No: E-248-2013/1

Updated: Jan-27-2014